NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001417

Registered date:08/10/2008

The efficacy and safety of autologous gamma/delta T cell transfer therapy after resection of intrahepatic cholangiocarcinoma or biliary tract cancer

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedIntrahepatic cholangiocarcinoma biliary tract cancer
Date of first enrollment2008/09/01
Target sample size30
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Gamma/delta T cells are injected on day0, day14, day28, day42, day56, day70, day84, day98. Gemcitabine on day-3, day4, day11, day25, day32, day39, day53, day60, day67, day81, day88, day95.

Outcome(s)

Primary OutcomeRelapse free survival Recurrence rate (1 and 2 years)
Secondary OutcomeOverall survival Response rate Survival rate (3 and 5 years) Response of tumor-related markers Immunological responses Safety

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaPatients who have: - Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them; - Active enteritis; - Active autoimmune diseases; - Active infections; - Other cancers; - Other serious complications; - Continuous systemic administration of steroids.

Related Information

Contact

public contact
Name Kazuhiro Kakimi
Address 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan Japan
Telephone 03-5805-3161
E-mail immunotherapy-admin@umin.ac.jp
Affiliation Graduate School of Medicine, The University of Tokyo Department of Immunotherapeutics
scientific contact
Name Norihiro Kokudo
Address 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan Japan
Telephone 03-5800-8654
E-mail
Affiliation The University of Tokyo Hospital Department of Hepatobiliary Pancreatic Surgery and Department of Artificial Organ and Transplantation Surgery